[Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors: results of a randomized trial] - PubMed

[Article in Italian]

Affiliations

• PMID: 9446253

Clinical Trial

[Effectiveness of sequential administration of G-CSF and GM-CSF after antineoplastic chemotherapy in patients with advanced tumors: results of a randomized trial]

[Article in Italian]

G Mustacchi et al. Tumori. 1997 Sep-Oct.

Abstract

Recent in vitro data have shown that growth factors are more effective when used in combination. This synergy between cytokines, when translated in a clinical setting, should permit a reduction of dosage, and therefore of toxicity. We sought to determine whether the sequential administration of low doses of G-CSF followed by low doses of GM-CSF could be effective both in protecting from neutropenia, and in reducing side effects. A randomized single blind phase III study was carried out. Patients considered to be eligible for the study were designated to receive a minimum of 3 chemotherapy cycles for treatment of metastatic or locally advanced cancer. Patients were randomized to receive, from the 8th day to the 13th day of cycle, G-CSF, 2.5 micrograms/kg/day s.c., or G-CSF, 2.5 micrograms/kg/day s.c. for the first 3 days, followed by GM-CSF, 2.5 micrograms/kg/day s.c. for the last 3 days. The number of delays in relation to the number of cycles, the number of patients whose therapies were deferred, and the total number of days of delay in relation to the total number of days of observation were significantly different, with far fewer delays in the group treated with the G-GM sequence. Our study confirms that the sequential administration of G-CSF and GM-CSF is highly synergistic. This synergy allows clinicians to administer chemotherapy treatments to pre-treated and/or elderly patients, with minimal risk of toxicity and no need for delays or dosage reduction.

Similar articles

• Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.

  Palmeri S, Leonardi V, Danova M, Porta C, Ferrari S, Fincato G, Citarrella P. Palmeri S, et al. Haematologica. 1999 Nov;84(11):1016-23. Haematologica. 1999. PMID: 10553163 Clinical Trial.

• Short-term administration of granulocyte-macrophage colony stimulating factor decreases hematopoietic toxicity of cytostatic drugs.

  Aglietta M, Monzeglio C, Pasquino P, Carnino F, Stern AC, Gavosto F. Aglietta M, et al. Cancer. 1993 Nov 15;72(10):2970-3. doi: 10.1002/1097-0142(19931115)72:10<2970::aid-cncr2820721018>3.0.co;2-0. Cancer. 1993. PMID: 8221563 Clinical Trial.

• Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.

  Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ. Arora M, et al. Biol Blood Marrow Transplant. 2004 Jun;10(6):395-404. doi: 10.1016/j.bbmt.2004.02.001. Biol Blood Marrow Transplant. 2004. PMID: 15148493 Clinical Trial.

• [Low-dose GM-CSF and dose intensity of antineoplastic agents].

  Pronzato P, Pensa F, Vaira F, Vigani A. Pronzato P, et al. Tumori. 1997 Sep-Oct;83(5 Suppl):S8-12. Tumori. 1997. PMID: 9446257 Review. Italian.

• Hematopoietic management in oncology practice. Part 1. Myeloid growth factors.

  Glaspy JA. Glaspy JA. Oncology (Williston Park). 2003 Nov;17(11):1593-603. Oncology (Williston Park). 2003. PMID: 14682110 Review.

Cited by

• Chemotherapy for advanced gastric cancer.

  Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Wagner AD, et al. Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article. Review.

Publication types

MeSH terms

Substances